Sotera Health Company (NASDAQ:SHC) Shares Sold by KBC Group NV

KBC Group NV trimmed its stake in Sotera Health Company (NASDAQ:SHC - Free Report) by 96.4% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,712 shares of the company's stock after selling 179,653 shares during the quarter. KBC Group NV's holdings in Sotera Health were worth $78,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Vanguard Group Inc. raised its position in Sotera Health by 1.2% in the fourth quarter. Vanguard Group Inc. now owns 14,923,546 shares of the company's stock worth $204,154,000 after acquiring an additional 173,341 shares during the period. Sculptor Capital LP bought a new stake in Sotera Health in the fourth quarter worth about $68,400,000. Dimensional Fund Advisors LP raised its position in Sotera Health by 27.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 3,143,955 shares of the company's stock worth $43,004,000 after acquiring an additional 673,979 shares during the period. Irenic Capital Management LP raised its position in Sotera Health by 4.3% in the fourth quarter. Irenic Capital Management LP now owns 2,909,163 shares of the company's stock worth $39,797,000 after acquiring an additional 120,832 shares during the period. Finally, Two Seas Capital LP raised its position in Sotera Health by 624.0% in the fourth quarter. Two Seas Capital LP now owns 2,896,136 shares of the company's stock worth $39,619,000 after acquiring an additional 2,496,136 shares during the period. 91.03% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

SHC has been the subject of several recent research reports. The Goldman Sachs Group upgraded shares of Sotera Health from a "neutral" rating to a "buy" rating and lifted their target price for the stock from $14.00 to $17.00 in a research note on Monday, May 5th. Wall Street Zen upgraded shares of Sotera Health from a "hold" rating to a "buy" rating in a research note on Saturday, June 28th. Barclays reduced their price objective on shares of Sotera Health from $15.00 to $13.00 and set an "overweight" rating for the company in a research note on Tuesday, June 24th. Finally, Piper Sandler reduced their price objective on shares of Sotera Health from $15.00 to $13.00 and set a "neutral" rating for the company in a research note on Wednesday, April 23rd. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $16.00.

Sotera Health Stock Performance

Sotera Health stock traded down $0.09 during midday trading on Friday, hitting $11.80. The stock had a trading volume of 806,138 shares, compared to its average volume of 1,234,713. The firm's fifty day moving average is $12.06 and its two-hundred day moving average is $12.27. The company has a market capitalization of $3.35 billion, a PE ratio of 19.03 and a beta of 1.81. Sotera Health Company has a 52-week low of $9.53 and a 52-week high of $17.08. The company has a current ratio of 2.46, a quick ratio of 2.19 and a debt-to-equity ratio of 5.55.

Sotera Health (NASDAQ:SHC - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.12 by $0.02. Sotera Health had a net margin of 2.24% and a return on equity of 41.08%. The business had revenue of $254.52 million during the quarter, compared to analyst estimates of $245.56 million. During the same period last year, the firm posted $0.13 EPS. The company's revenue was up 2.6% on a year-over-year basis. On average, research analysts forecast that Sotera Health Company will post 0.61 EPS for the current year.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.